Last reviewed · How we verify
N-13 ammonia intravenous injection
N-13 ammonia is a positron-emitting radiopharmaceutical that accumulates in viable myocardium proportional to regional blood flow, enabling visualization of cardiac perfusion.
N-13 ammonia is a positron-emitting radiopharmaceutical that accumulates in viable myocardium proportional to regional blood flow, enabling visualization of cardiac perfusion. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.
At a glance
| Generic name | N-13 ammonia intravenous injection |
|---|---|
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Drug class | Positron emission tomography (PET) imaging agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
N-13 ammonia is taken up by myocardial cells via the glutamate-glutamine cycle and becomes trapped intracellularly, with uptake correlating to regional myocardial blood flow. The positron emissions are detected by PET imaging to create maps of myocardial perfusion, allowing assessment of coronary artery disease, viability, and ischemia. This enables non-invasive evaluation of cardiac function and blood flow distribution.
Approved indications
- Myocardial perfusion imaging for assessment of coronary artery disease
- Evaluation of myocardial viability
- Assessment of regional myocardial blood flow
Common side effects
Key clinical trials
- Safety of PET MPI Using the CRCHUM N-13 Ammonia (PHASE4)
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (PHASE2)
- Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
- Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT
- Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: